Growth Metrics

Eli Lilly (LLY) Shareholder's Equity (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 17.57%
Dec 31, 2025 11.25%
Sep 30, 2025 43,151.99%
Jun 30, 2025 97.46%
Mar 31, 2025 -986.99%
Dec 31, 2024 113.06%
Sep 30, 2024 -2,662.86%
Jun 30, 2024 101.71%
Mar 31, 2024 -42.70%
Dec 31, 2023 -6,595.56%
Sep 30, 2023 97.61%
Jun 30, 2023 50.09%
Mar 31, 2023 -4,250.88%
Dec 31, 2022 102.12%
Sep 30, 2022 -0.19%
Jun 30, 2022 -1.48%
Mar 31, 2022 2.71%
Dec 31, 2021 2.74%
Sep 30, 2021 -152.35%
Jun 30, 2021 383.09%
Mar 31, 2021 53.62%
Dec 31, 2020 0.90%
Sep 30, 2020 -1,195.99%
Jun 30, 2020 207.40%
Mar 31, 2020 -108.33%
Dec 31, 2019 1.16%
Sep 30, 2019 1.14%
Jun 30, 2019 271.34%
Mar 31, 2019 -6,614.26%
Dec 31, 2018 -731.11%
Sep 30, 2018 100.30%
Jun 30, 2018 29.51%
Mar 31, 2018 -1,724.33%
Dec 31, 2017 80.56%
Sep 30, 2017 59.99%
Jun 30, 2017 40.06%
Mar 31, 2017 -2,283.64%
Dec 31, 2016 92.63%
Sep 30, 2016 -7,878.26%
Jun 30, 2016 103.39%
Mar 31, 2016 -5,812.63%
Dec 31, 2015 -99.88%
Sep 30, 2015 3.64%
Jun 30, 2015 -1.61%
Mar 31, 2015 -2.78%
Dec 31, 2014 -12.99%
Sep 30, 2014 -1.75%
Jun 30, 2014 -1.93%
Mar 31, 2014 4.01%
Dec 31, 2013 4.35%
Sep 30, 2013 10.89%
Jun 30, 2013 1.88%
Mar 31, 2013 1.29%
Dec 31, 2012 -8.04%
Sep 30, 2012 12.22%
Jun 30, 2012 -3.47%
Mar 31, 2012 9.46%
Dec 31, 2011 -10.07%
Sep 30, 2011 5.47%
Jun 30, 2011 2.46%
Mar 31, 2011 12.19%
Dec 31, 2010 0.12%
Sep 30, 2010 21.20%
Jun 30, 2010 -2.17%
Mar 31, 2010 10,521.62%
Dec 31, 2009 -99.01%
Sep 30, 2009 15.71%